Head to Head Analysis: PhaseBio Pharmaceuticals (NASDAQ:PHAS) Vs. Alpine Immune Sciences (NASDAQ:ALPN)
Head to Head Analysis: PhaseBio Pharmaceuticals (NASDAQ:PHAS) Vs. Alpine Immune Sciences (NASDAQ:ALPN)
PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) and Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.
PhaseBio Pharmicals（纳斯达克股票代码：PHAS — 获取评级）和Alpine Immune Sciences（纳斯达克股票代码：ALPN — 获取评级）都是小型医疗公司，但哪个是更好的投资？我们将根据两家企业的风险、估值、机构所有权、分析师建议、收益、盈利能力和股息进行比较。
Institutional & Insider Ownership
机构所有权和内部所有权
49.0% of PhaseBio Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Alpine Immune Sciences shares are held by institutional investors. 9.9% of PhaseBio Pharmaceuticals shares are held by insiders. Comparatively, 54.7% of Alpine Immune Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
PhaseBio Pharmicals49.0％的股份由机构投资者持有。相比之下，Alpine Immune Sciences有79.0％的股票由机构投资者持有。PhaseBio Pharmicals的9.9％的股票由内部人士持有。相比之下，Alpine Immune Sciences有54.7％的股份由内部人士持有。强大的机构所有权表明，捐赠基金、大型基金经理和对冲基金认为，从长远来看，股票的表现将超过市场。
Profitability
盈利能力
This table compares PhaseBio Pharmaceuticals and Alpine Immune Sciences' net margins, return on equity and return on assets.
该表比较了PhaseBio制药和Alpine Immune Sciences的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| PhaseBio Pharmaceuticals | -12,572.13% | N/A | -174.38% |
| Alpine Immune Sciences | -169.82% | -47.34% | -23.12% |
| 净利润 | 股本回报率 | 资产回报率 | |
| PhaseBio制药 | -12,572.13% | 不适用 | -174.38% |
| 阿尔卑斯免疫科学 | -169.82% | -47.34% | -23.12% |
Analyst Recommendations
分析师建议
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PhaseBio Pharmaceuticals | 0 | 5 | 0 | 0 | 2.00 |
| Alpine Immune Sciences | 0 | 0 | 3 | 0 | 3.00 |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| PhaseBio制药 | 0 | 5 | 0 | 0 | 2.00 |
| 阿尔卑斯免疫科学 | 0 | 0 | 3 | 0 | 3.00 |
PhaseBio Pharmaceuticals currently has a consensus target price of $4.50, suggesting a potential upside of 4,636.84%. Alpine Immune Sciences has a consensus target price of $15.67, suggesting a potential upside of 157.68%. Given PhaseBio Pharmaceuticals' higher probable upside, equities analysts clearly believe PhaseBio Pharmaceuticals is more favorable than Alpine Immune Sciences.
PhaseBio Pharmicals目前的共识目标价为4.50美元，这表明潜在的上涨空间为4,636.84％。Alpine Immune Sciences的共识目标价为15.67美元，表明潜在的上涨空间为157.68％。鉴于PhaseBio Pharmicals可能更高的上行空间，股票分析师显然认为PhaseBio Pharmicals比Alpine Immune Sciences更
Risk and Volatility
风险和波动性
PhaseBio Pharmaceuticals has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500. Comparatively, Alpine Immune Sciences has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.
PhaseBio Pharmicals的beta值为2.87，这表明其股价的波动性比标准普尔500指数高187％。相比之下，Alpine Immune Sciences的beta值为1.5，这表明其股价的波动性比标准普尔500指数高50％。
Valuation & Earnings
估值与收益
This table compares PhaseBio Pharmaceuticals and Alpine Immune Sciences' gross revenue, earnings per share (EPS) and valuation.
该表比较了PhaseBio制药和Alpine Immune Sciences的总收入、每股收益（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PhaseBio Pharmaceuticals | $10.83 million | 0.44 | -$131.07 million | ($2.13) | -0.04 |
| Alpine Immune Sciences | $23.44 million | 7.89 | -$50.33 million | ($1.92) | -3.17 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| PhaseBio制药 | 1,083 万美元 | 0.44 | -1.3107 亿美元 | (2.13 美元) | -0.04 |
| 阿尔卑斯免疫科学 | 2344 万美元 | 7.89 | -5,033 万美元 | (1.92 美元) | -3.17 |
Alpine Immune Sciences has higher revenue and earnings than PhaseBio Pharmaceuticals. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than PhaseBio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Alpine Immune Sciences的收入和收益高于PhaseBioAlpine Immune Sciences的市盈率低于PhaseBio Pharmicals，这表明它目前是这两只股票中更实惠的一只。
Summary
摘要
Alpine Immune Sciences beats PhaseBio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
比较两只股票的14个因素中，Alpine Immune Sciences在10个因素上击败了PhaseBio
About PhaseBio Pharmaceuticals
关于PhaseBio制药
(Get Rating)
（获取评分）
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
PhaseBio Pharmicals, Inc. 是一家处于临床阶段的生物制药公司，从事心血管疾病新疗法的开发和商业化。该公司的产品线包括：bentracimab（PB2452），一种用于抗血小板疗法的新型逆转药物 ticagrelor，pemziviptadil（PB1046），一种用于治疗肺动脉高压的每周一次的血管活性肠道肽受体激动剂，以及用于治疗耐药性高血压的口服药物 PB6440。该公司由 Ashutosh Chilkoti 和 Clay Bernardin Thorp 于 2002 年 1 月创立，总部位于宾夕法尼亚州马尔文。
About Alpine Immune Sciences
关于阿尔卑斯免疫科学
(Get Rating)
（获取评分）
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Alpine Immune Sciences, Inc. 是一家临床阶段的生物制药公司，专注于发现和开发用于治疗癌症、自身免疫/炎症性疾病和其他疾病的蛋白质免疫疗法。其产品线包括用于治疗自身免疫和炎症性疾病的诱导性 T 细胞共刺激剂 (ICOS) /分化集群 28 (CD28) 拮抗剂项目 ALPN-101；ALPN-202，一种用于治疗癌症的条件性 CD28 共刺激剂和双检查点抑制剂；以及用于治疗 B 细胞介导的炎症和自身免疫性疾病的双 B 细胞因子拮抗剂 ALPN-303。该公司与 AbbVie Ireland Unlimited Company 签订了开发 ALPN-101 的合作协议；与 Adaptimmune Therapeutics plc 签订了开发下一代 SPEAR T 细胞产品的合作协议。Alpine Immune Sciences, Inc. 成立于 2007 年，总部位于华盛顿州西雅图。
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收PhaseBio制药日报的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收PhaseBio Pharmicals及相关公司的最新新闻和分析师评级的简明每日摘要。